文章摘要
Jin Lü,Xiufeng Cao,Bin Zhu,Lü Ji.[J].南京医科大学学报,2009,29(5):335~339
A prospective study: intraoperative 125I radioactive seed implant therapy in advanced esophageal squamous cell carcinoma
投稿时间:2009-05-13  
DOI:10.7655
中文关键词: 
英文关键词: esophageal squamous cell carcinoma  125I radioactive seed brachytherapy  esophagectomy
基金项目:
作者单位
Jin Lü Oncology Center Surgery of Nanjing First Hospital Affiliated to Nanjing Medical University and Oncology Center of Nanjing Medical University, Nanjing 210006,China 
Xiufeng Cao  
Bin Zhu  
Lü Ji  
摘要点击次数: 1315
全文下载次数: 162
中文摘要:
      
英文摘要:
      Objective: To investigated the role of intraoperative iodine-125 (125I) brachytherapy as a treatment option for advanced thoracic esophageal squamous cell carcinoma (ESCC). Methods: Using preoperative computed tomography (CT)-based staging criteria, between 2000 and 2008, 298 patients with ESCC (stage II-III) were enrolled in this prospective study. With informed consent, patients were randomized into two groups: intraoperative 125I seed implantation and surgery alone (control group). Twenty to forty 125I seeds (0.5 mCi per seed), with a total activity in 10~30 mCi, and a matched peripheral dose (MPD) of 60~70 Gy, were implanted under direct visualization. The surgical procedure used in this study was either a radical resection, which involved an esophagectomy through a left thoracotomy with two-field lymphadenectomy, or palliative resection. The postoperative complications were observed and recorded. The location and quality assessment of 125I seeds were assessed using CT scans or X-ray imaging. The short-term efficacy was evaluated according to WHO criteria. The 1, 3, 5 and 7-year survival rates were determined on follow-up. Results: There was no displacement or loss of 125I seeds. The local recurrence rates in the intraoperative 125I seed implantation group and control group were 14.9% and 38.7%, respectively (P < 0.05). An objective response rate of 92% was observed in the seed implant group, which was significantly higher than 0% in the control group (P < 0.05). There was no significant difference between the two groups when comparing of complications (P > 0.05). The 1-year survival rate of the two groups were not significantly different (P > 0.05). However, the 3, 5 and 7-year survival rates in the united 125I group (64%, 55.3% and 8%, respectively) were statistically different from those in the control group (52%, 29.1% and 1.4%,respectively)(P < 0.05). Conclusion: Intraoperative 125I seed implantation is safe and effective for advanced ESCC. Seed implantation may reduce the local recurrence rate and improve survival in patients with ESCC. The MPD of 60~70 Gy, with single 125I seed activity of 0.5 mCi, is reasonable.
查看全文   查看/发表评论  下载PDF阅读器
关闭